Kenilin Brand Formulations

The FDA published guidelines in 2004 for a new type of combination drugs (pharmaceutical and botanical).  Kenilin is not yet approved but is in the process of running approved studies that permit the first human trials to commence at Rose Medical Center, Denver Colorado and State University of New York (Downstate Medical Center, Brooklyn, NY).

The Name Kenilin

Kenilin is the name of both our medicine and our company, derived from the first names of the original developers of the product, Kenneth Burton MD and Lindsey Berkson MA CNS.  Dr. Jack W. Moncrief, neprhologist and coninventor of  Continuous Ambulatory Peritoneal Dialysis (CAPD) has been part of the co-development on a continuing basis.

“If we are correct, and we believe that we are, Kenilin will become THE way to treat chronic wounds. No one else will use any of the other tools when they can heal with the simplicity of the technology we are talking about.”   
          -  Jack Moncrief, MD